(Q44398234)

English

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

scientific article published on 27 February 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide (English)

1 reference

Europe PubMed Central

2 December 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

2 December 2017

author name string

J T Backman

2

1 reference

Europe PubMed Central

2 December 2017

M Neuvonen

3

1 reference

Europe PubMed Central

2 December 2017

P J Neuvonen

4

1 reference

Europe PubMed Central

2 December 2017

publication date

27 February 2003

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

46

1 reference

Europe PubMed Central

2 December 2017

347-351

1 reference

Europe PubMed Central

2 December 2017

3

1 reference

Europe PubMed Central

2 December 2017

https://scigraph.springernature.com/pub.10.1007/s00125-003-1034-7

0 references

Clinical pharmacokinetics and pharmacodynamics of repaglinide

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Gemfibrozil greatly increases plasma concentrations of cerivastatin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

1 reference

https://api.crossref.org/works/10.1007%2FS00125-003-1034-7

21 January 2018

CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide

1 reference

https://pubmed.ncbi.nlm.nih.gov/12687332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

1 reference

https://pubmed.ncbi.nlm.nih.gov/12687332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-003-1034-7

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44398234&oldid=2143924718"